PCI Biotech Holding ASA
Oslo Stock ExchangeTotal Valuation
PCI Biotech Holding ASA carries a market capitalization of 2.61M, placing it among publicly traded companies globally. Its enterprise value stands at 33.75M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 2.61M |
| Enterprise Value | 33.75M |
Share Statistics
PCI Biotech Holding ASA currently has 37.33M shares outstanding.
| Shares Outstanding | 37.33M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | 0.70 |
| P/TBV Ratio | 1.68 |
| P/FCF Ratio | -2.61 |
| P/OCF Ratio | -2.61 |
Financial Position
PCI Biotech Holding ASA maintains a current ratio of 9.69, meaning it holds 9.7x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 1.22, indicating moderate leverage, while an interest coverage ratio of 45.43 demonstrates strong ability to service its debt obligations.
| Current Ratio | 9.69 |
| Quick Ratio | 8.49 |
| Debt / Equity | 1.22 |
| Debt / EBITDA | -0.02 |
| Interest Coverage | 45.43 |
Financial Efficiency
| Return on Equity (ROE) | -8.63 |
| Return on Assets (ROA) | -39.94 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
PCI Biotech Holding ASA's stock has declined approximately -95.85799% over the past 52 weeks. The 50-day moving average sits at 0.18, while the 200-day moving average is 0.44.
| Beta (5Y) | N/A |
| 52-Week Price Change | -95.85799% |
| 50-Day Moving Average | 0.18 |
| 200-Day Moving Average | 0.44 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -30.71M, while operating income came in at -30.71M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -30.71M |
| Pretax Income | -29.11M |
| Net Income | -29.11M |
| EBITDA | -30.71M |
| EBIT | -30.71M |
| Earnings Per Share (EPS) | -0.78 |
Balance Sheet
PCI Biotech Holding ASA holds 45.58M in cash and equivalents against 572,000.00 in total debt, resulting in a net debt position of -45.58M. Total book value stands at 111.98M, with working capital of 46.61M providing operational flexibility.
| Cash & Cash Equivalents | 45.58M |
| Total Debt | 572,000.00 |
| Net Debt | -45.58M |
| Equity (Book Value) | 111.98M |
| Book Value Per Share | 3.00 |
| Working Capital | 46.61M |
Cash Flow
PCI Biotech Holding ASA produced -30.13M in operating cash flow over the past twelve months.
| Operating Cash Flow | -30.13M |
| Capital Expenditures | N/A |
| Free Cash Flow | -30.13M |
| FCF Per Share | -0.81 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | 0.63 |
| FCF Yield | -38.25 |
Stock Splits
PCI Biotech Holding ASA's most recent stock split took place on September 17, 2018 with a 1000:1077 split ratio.
| Last Split Date | 9/17/2018 |
| Split Ratio | 1000:1077 |
Scores
PCI Biotech Holding ASA posts an Altman Z-Score of 7.56, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 7.56 |